^
Association details:
| Biomarker: | KDM6A mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Vyxeos (cytarabine/daunorubicin liposomal formulation) (DNA synthesis inhibitor, Topoisomerase II inhibitor, DNA polymerase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
KDM6A Mutation in AML
Published date:
09/14/2020
Excerpt:
We annotated a cohort of 293 AML patients...Total of eleven patients (3.75%) were found to have KDM6A mutation….one patient required two cycles of daunorubicin and cytarabine before achieving CR, and at the time of relapse was noted to have the same mutation.
